These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30097824)

  • 1. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
    Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
    J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response.
    Miller C; Guillaume D; Dusenbery K; Clark HB; Moertel C
    J Neurosurg Pediatr; 2017 Mar; 19(3):319-324. PubMed ID: 28009226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
    N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
    Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
    J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma.
    Knight T; Shatara M; Carvalho L; Altinok D; Poulik J; Wang ZJ
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27474. PubMed ID: 30251337
    [No Abstract]   [Full Text] [Related]  

  • 11. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
    Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
    Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
    Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Boull C; Hook K; Moertel C; Maguiness S
    Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
    Paul MR; Pehlivan KC; Milburn M; Yeh-Nayre L; Elster J; Crawford JR
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e730-e737. PubMed ID: 32398601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib Effective in Pediatric Glioma.
    Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Karajannis MA; Legault G; Fisher MJ; Milla SS; Cohen KJ; Wisoff JH; Harter DH; Goldberg JD; Hochman T; Merkelson A; Bloom MC; Sievert AJ; Resnick AC; Dhall G; Jones DT; Korshunov A; Pfister SM; Eberhart CG; Zagzag D; Allen JC
    Neuro Oncol; 2014 Oct; 16(10):1408-16. PubMed ID: 24803676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
    Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.